EP4349410A3 — A composition for use in the therapeutic treatment of a cancer or a tumor
Assigned to Columbia University in the City of New York · Expires 2024-06-05 · 2y expired
What this patent protects
The present disclosure provides a composition for use in the therapeutic treatment of a cancer or a tumor in a patient, said composition comprising an isolated Dual-Specificity Tyrosine-Phosphorylation-Regulated Protein Kinase 1 (DYRK1) protein and isolated prolyl hydroxylase (PH…
USPTO Abstract
The present disclosure provides a composition for use in the therapeutic treatment of a cancer or a tumor in a patient, said composition comprising an isolated Dual-Specificity Tyrosine-Phosphorylation-Regulated Protein Kinase 1 (DYRK1) protein and isolated prolyl hydroxylase (PHD) protein, wherein the composition increases degradation of Hypoxia-Inducible Factor-α (HIFα) in cancer cells or tumor cells in the patient and/or decreases half-life of HIFα in the cancer cells or the tumor cells in the patient.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.